Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China.

CURRENT STATUS: ACCEPTED

Dawei Wang
Wuhan University Zhongnan Hospital

Yimei Yin
Wuhan University Zhongnan Hospital

Chang Hu
Wuhan University Zhongnan Hospital

Xing Liu
Wuhan University Zhongnan Hospital

Xingguo Zhang
Xi-shui Hospital, Hubei Province

Shuliang Zhou
Wuhan University Zhongnan Hospital

Mingzhi Jian
Center for Disease control and Prevention. Shaoxing

Haibo Xu
Wuhan University Zhongnan Hospital

John Prowle
The Royal London Hospital, Barts Health NHS Trust, London

Bo Hu
Wuhan University Zhongnan Hospital

Yirong Li
Wuhan University Zhongnan Hospital

Zhi-Yong Peng
Abstract

Background In December 2019, Coronavirus Disease 2019 (COVID-19) outbreak was reported from Wuhan, China. Information on the clinical course and prognosis of COVID-19 was not thoroughly described. We described the clinical courses and prognosis in COVID-19 patients.

Methods Retrospective case series of COVID-19 patients from Zhongnan Hospital of Wuhan University in Wuhan, and Xi-shui Hospital, Hubei Province, China, up to February 10, 2020. Epidemiological, demographic and clinical data were collected. Clinical course of survivors and non-survivors were compared. Risk factors for death were analyzed.

Results A total of 107 discharged patients with COVID-19 were enrolled. The clinical course of COVID-19 presented as a tri-phasic pattern. Week 1 after illness onset was characterized by fever, cough, dyspnea, lymphopenia and radiological multilobar pulmonary infiltrates. In severe cases, thrombocytopenia, acute kidney injury, acute myocardial injury or adult respiratory distress syndrome were observed. During week 2, in mild cases, fever, cough and systemic symptoms began to resolve and platelet count rose to normal range, but lymphopenia persisted. In severe cases, leukocytosis, neutrophilia and deteriorating multi-organ dysfunction were dominant. By week 3, mild cases had clinically resolved except for lymphopenia. However, severe cases showed persistent lymphopenia, severe acute respiratory dyspnea syndrome, refractory shock, anuric acute kidney injury, coagulopathy, thrombocytopenia and death. Older age and male sex were independent risk factors for poor outcome of the illness.

Conclusions A period of 7–13 days after illness onset is the critical stage in COVID-19 course. Age and male gender were independent risk factors for death of COVID-19.

Background

In late 2019 a novel coronavirus, designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of COVID-19 in Wuhan, a city in the Hubei province of China.\textsuperscript{1,2} Full-genome sequencing and phylogenetic analysis indicated that SARS-CoV-2 is a betacoronavirus in the same subgenus as the SARS virus, but in a different clade.\textsuperscript{2} SARS-CoV-2 is 96% identical at the whole-genome level to a bat coronavirus, and suggesting that bats are the primary source.\textsuperscript{4, 5}
Epidemiologic investigations of initial cases showed COVID-19 was linked with exposure to Wuhan seafood market which also sold live rabbits, snakes, and other animals. \(^6\) Subsequently, human-to-human transmission among close contacts has been the primary mechanism of transmission. \(^7\) The disease has spread rapidly around the world and more than 410,000 cases of COVID-19 have been reported. COVID-19 outbreak has been reported in other countries, mainly among travelers from Wuhan and their contacts. \(^8,9\) WHO has declared this disease a pandemic.

The incubation period of COVID-19 is thought to be up to 14 days following exposure. \(^6,7,10\) The principal presenting features of COVID-19 are fever, cough, dyspnea and bilateral infiltrates on chest imaging. \(^11,12\) Approximately 20 percent of patients progress to multi-organ dysfunction (including respiratory failure, septic shock, acute cardiac injury or acute renal failure). \(^11-13\) However, a complete picture of the clinical course of COVID-19 has not been described thoroughly. \(^14\) Except for infection control and supportive therapy, there is no specific therapy of COVID-19. Multiple organ support therapy is the corner stone in the treatment of critically ill patients with COVID-19. \(^13,14\) Early recognition of risk factors for death would be useful to identify those potentially needing critical care at an early stage. Accordingly, a study was conducted to track clinical course along the entire disease course. Risk factor analysis was performed to reveal important clinical features associated with the poor outcome.

**Methods**

**Study design and participants**

This case series was approved by the institutional ethics board of Zhongnan Hospital of Wuhan University and Xishui People's Hospital (No. 2020020). All the discharged (alive at home and dead) patients with confirmed COVID-19 from Zhongnan Hospital of Wuhan University and Xishui People's Hospital up to February 10, 2020, were enrolled. Oral consent was obtained from patients or patients’ relatives. Zhongnan Hospital, located in Wuhan, Hubei Province, the endemic areas of COVID-19, is one of the major tertiary teaching hospitals and responsible for the treatments for COVID-19 assigned by the government. Xishui People's Hospital located in Huanggang city, another early endemic centre
of COVID-19 in Hubei province. Totally, about 340 heath care workers provided care to COVID-19
patients in the two medical center from January to February, 2020. All patients with COVID-19
enrolled in this study were diagnosed according to World Health Organization interim guidance.\textsuperscript{15} The
methodology of RT-PCR used has been previously reported.\textsuperscript{13} The time frame was overlaped with
JAMA cohort, and 88 patients in the current report have been included in JAMA cohort\textsuperscript{13}.

Data collection
The medical records of patients were analyzed by the research team of the Department of Critical
Care Medicine, Zhongnan Hospital of Wuhan University. Epidemiological, clinical, laboratory, and
radiological characteristics and treatment and outcomes data were obtained with data collection
forms from electronic medical records and reviewed by a trained team of physicians. Information
recorded included demographic data, medical history, exposure history, underlying comorbidities,
symptoms, signs, laboratory findings, chest computed tomographic (CT) scans, treatment measures
(i.e., antiviral therapy, corticosteroid therapy, respiratory support, kidney replacement therapy) and
outcome. The date of disease onset was defined as the day when the first symptom was noticed.
Acute respiratory distress syndrome (ARDS) was defined according to the Berlin definition.\textsuperscript{16} Acute
kidney injury (AKI) was identified according to the Kidney Disease: Improving Global Outcomes
definition.\textsuperscript{17} Cardiac injury was defined if the serum levels of cardiac biomarkers (e.g., troponin I) were
above the 99th percentile of upper reference limit or if new abnormalities were shown in
echocardiography. Times from onset of disease to hospital admission, dyspnea, ARDS, ICU admission
and hospital discharge were recorded.

Statistical analysis
Categorical variables were described using frequencies and percentage, while continuous variables
were described using mean, median, and interquartile range (IQR) values. Means for continuous
variables were compared using independent group Student’s t tests when the data were normally
distributed and the Mann-Whitney test when they were not. Proportions for categorical variables were compared using the \( \chi^2 \) test, although Fisher’s exact test was used when the data were sparse. Univariate analyses were performed to evaluate the risk factors associated with death. Multiple logistic regression analysis was used to identify independent predictors of mortality. All the tests were two-tailed and p-value less than 0.05 was considered statistically significant. All analyses were processed by SPSS for Windows version 17.0 (SPSS, Chicago, IL, USA).

Results

**Basic Characteristics**

As of February 10, 2020, 544 patients admitted to Zhongnan Hospital and Xishui hospital and 107 patients discharged. Basic characteristics of the 107 patients (95 from Zhongnan and 12 from Xi-Shui) are shown in Table 1. There were 88 survivors and 19 non-survivors. Median age was 51 years (IQR, 36-65; range, 19-92 years), 57 (53.3\%) were male. Median times from first symptoms to hospital admission, dyspnea, and ARDS were 7 days (IQR, 3.5-9), 5.5 days (IQR, 2-9.3), and 7.5 days (IQR, 4.3-11), respectively. Median length of hospital stay was 11 days (IQR, 7-15). In this cohort of 107 patients, hypertension (26 [24.3\%]), cardiovascular disease (13 [12.1\%]) and diabetes (11 [10.3\%]) were the most common coexisting conditions. The most common symptoms at onset of illness were fever (104 [97.2\%]), dry cough (67 [62.6\%]), fatigue (69 [64.5\%]), dyspnea (35 [32.7\%]), anorexia (33 [30.8\%]) and myalgia (33 [30.8\%]). Less common symptoms were sore throat, headache, dizziness, abdominal pain, diarrhea, nausea, and vomiting. At hospital admission median respiratory rate was 20/minute (IQR, 19-21) and mean arterial pressure was 89 mmHg (IQR, 83-98).

In comparison to the 88 hospital survivors, the 19 non-survivors were significantly older (median age, 73 years [IQR, 64-81] vs 44.5 years [IQR, 35-58.8]; p < .001) and were predominantly male (16 [84.2\%] vs 41 [46.6\%]; p=.003). Non-survivors were more likely to have underlying comorbidities, including hypertension (10 [52.6\%] vs 16 [18.2\%]; P=.001) and other cardiovascular disease (7 [36.8\%] vs 6 [6.8\%]; P=.002). Compared with the survivors, non-survivors were more likely to report dyspnea (15 [78.9\%] vs 20 [22.7\%]; P < .001) and diarrhea (4 [21.1\%] vs 3 [3.4\%]; P=.018) at presentation. At hospital admission respiratory rate was higher in survivors than in non-survivors (22
Similarly, mean arterial pressure was higher in non-survivors than in survivors (95mmHg [IQR 89-101] vs 88mmHg [83-96]; P=.019).

**Laboratory values and radiographic findings**

Laboratory values and radiographic findings at hospital admission are shown in Table 2. Lymphopenia (0.9×10⁹/L [0.7-1.2]) and prolonged prothrombin time (12.8[11.9-13.5]) at admission were prominent features. 90 (84.1%) patients showed multi-lobar involvement on initial radiographs. 105 (98.1%) patients showed bilateral involvement on chest CT scan during hospitalization. Compared with survivors, on admission non-survivors had higher neutrophil counts (5.4×10⁹/L[3.2-8.5] vs 2.8×10⁹/L [2-3.9], P≤0.001, lower platelet count (122×10⁹/L [83-178] vs 178 [139-207], P=0.006) and higher D-dimer level (439 mg/L [202-1991] vs 191mg/L [108-327], P=0.003). Admission values of blood urea, creatinine, highly sensitive troponin I, serum creatine kinase, creatine kinase-MB, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase were also significantly higher in the non-survivors.

**Clinical Profile and Laboratory Findings in COVID-19 Patients**

Temporal clinical profiles in 107 patients with COVID-19 are shown in Figure 2. Trends of temperature and onset of positive nucleic acid amplification test (NAAT) were consistent. Fever typically lasts for about 10 days. Most patients (about 75%) demonstrated positive NAAT results (measured every 2-3 days) within 9 days after symptoms onset. The median time from illness onset to first positive result of NAAT was 7 days (3.0-10.0) and the duration of active viral shedding was 13 days (IQR, 10-22.3) in survivors. In the majority of cases development of ARDS and need for endotracheal intubation occurred within 9 days after symptoms onset.

Dynamic body temperature and laboratory findings in 107 COVID-19 patients are shown in supplementary Figure 1. During the first week after symptoms onset, fever was prominent and more severe in the non-survivors. Body temperature gradually normalized in the second week. In general, white blood cell counts and neutrophils counts were in normal range during week 1, with leukocytosis
and neutrophilia as later findings. Lymphopenia was common throughout the disease’s course and the lymphocytes count dropped more in non-survivors. Platelets counts decreased slightly in the first week, then rose back to normal range rapidly in survivors, but remained low in non-survivors. Mild prolongation of prothrombin time (PT) during the illness course was observed, with no difference between survivors and non-survivors. D-dimer level was Elevated in the non-survivors during the late stage of illness. In the early stage of the illness, higher levels of creatine kinase, creatine kinase-MB, lactate dehydrogenase, alanine aminotransferase and aspartate aminotransferase were observed in the non-survivors than those in the survivors. In non-survivors, blood urea and creatinine levels progressively increased until death.

**Complications, treatments and outcome**

Common complications included ARDS (28[26.2%]), shock (22 [20.6%]), AKI (14[13.1%]) and acute cardiac injury (12[11.2%]) (Table 3). Non-survivors were more likely to have one of these complications than survivors. Secondary infection included 1 case of bacteremia caused by Staphylococcus caprae and 4 cases of bacteria pneumonia caused by Acinetobacter baumannii. Co-infection with virus included 1 patient tested positive for influenza A, two for influenza B, three for respiratory syncytial virus, three for parainfluenza and 3 for adenovirus. Almost all patients received antiviral therapy (105 [98.1%]). Among of them, 95(88.8%) patients received oseltamivir and 33 (30.8%) patients received arbidol. Glucocorticoids were administered in 62 [57.9%] patients. Oxygen therapy was applied in (80 [74.8%] patients. In total, 20 patients required invasive mechanical ventilation. On day 1 of invasive mechanical ventilation, the median PaO2/FiO2 ratio was 103 (IQR 58-172) and the median APACHE II score was 25 (IQR 17-32). Three patients received extracorporeal membrane oxygenation (ECMO) therapy, Two of them survived and were discharged at day 26 and day 32, and one died due to sudden cardiac arrest after connection to the ECMO circuit. The causes of death included refractory ARDS (15 [78.9%]), septic shock (1 [5.3%]), sudden cardiac arrest (1 [5.3%]), hemorrhagic shock (1 [5.3%]) and acute myocardial infarction (1 [5.3%]).
Risk factors associated with death for COVID-19

On univariate analysis, risk factors associated with death at hospital admission were older age, male gender, hypertension, diabetes, cardiovascular disease, raised white blood cell counts, elevated level of neutrophil counts, thrombocytopenia, creatine kinase-MB, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase and creatinine (Table 4). On multivariable analysis, older age and male gender remained significant independent risk factors for death (Table 5).

Discussion

Studies on COVID-19 have generally been limited to the description of the initial clinical, haematological, radiological and microbiological findings. Herein, we firstly described the clinical course of virologically confirmed COVID-19. This study enrolled 107 discharged patients with COVID-19 which included 88 survivors and 19 non-survivors. We also analyzed the prognosis factors and found that age and male gender were the independent risk factor for mortality.

This study showed the clinical course of COVID-19 presented as a tri-phasic pattern. Week 1 was characterized by fever, cough, dyspnea and other systemic symptoms. Most positive NAAT results could be obtained in week 1, which suggested that the symptoms were largely related to the effect of viral replication. In surviving patients, laboratory abnormalities included lymphopenia and prolonged prothrombin time. In non-survivors, emergence of systemic inflammation was evidenced by higher fever, respiratory rate, WBC counts and neutrophils count. Subsequently, multiple organ dysfunction syndrome (MODS) occurred with thrombocytopenia, renal failure, acute myocardial injury and ARDS. Notably, there was an obvious drop in body temperature around day 7, probably in relation to the widespread use of methylprednisolone as a rescue therapy.

During weeks 2 of illness, NAAT test became negative in surviving patients at a median of 13 days after illness onset. At the same time fever, cough and systemic symptoms began to resolve. However, lymphocyte counts still remained low, even as symptomatic illness resolved. This suggests that the lymphocytes are the main target of SARS-CoV-2 infection and the lymphocyte counts needs some time to recover. In the non-survivors, clinical status deteriorated and MODS developed during the second week.
In week 3, the organ functions improved in survivors, but continued to deteriorate in the non-survivors. The lymphocyte counts dropped further and immune dysfunction became obvious in the non-survivors. These patients developed severe ARDS necessitating ventilation and even ECMO support, septic shock supported by vasopressors, and an- end stage renal failure requiring continuous renal replacement therapy. Coagulation dysfunction and thrombocytopenia also developed. Death was inevitable due to multiorgan failure.

Notably, most non-survivors in our study were old male. Multivariate analysis showed older age and male gender were independent risk factors for death. A recent study examining single-cell RNA expression profiling of angiotensin converting enzyme 2 (ACE2), the cellular receptor of SARS-CoV-2, showed that Asian males had an extremely large number of ACE2-expressing cells in the lung. A finding that might underlie the higher risk of death in this population.

After the incubation period, the frequent manifestations of COVID-19 were fever, cough, dyspnea, and bilateral infiltrates on chest imaging. Evidence has shown that SARS-CoV-2 was found in the loose stool of a patient and potential transmission through the faecal–oral route should be considered. Consistent with the finding, some patients showed digestive symptoms (e.g. abdominal pain, diarrhea, nausea, and vomiting) at the illness onset. Multi-lobar involvement on initial chest CT was shown in most of our patients, consistent with a primary pulmonary method of acquisition. Notably, the mean arterial pressure was higher in non-survivors than survivors because the comorbidity of hypertension was more common in non-survivors.

Until now, no fully proven and specific antiviral treatment for the SARS-CoV-2 infection exists. Organ support therapy is the corner stone in the treatment of critically ill patients with SARS-CoV-2 infection. Remdesivir, a novel nucleotide analog antiviral drug has been used in the first case with COVID-19 in the US and a clinical trial of remdesivir in SARS-CoV-2 infection is in progress. Remdesivir and chloroquine have been shown to effectively inhibit the SARS-CoV-2 in Vero E6 cells. In hospitalized adult patients with severe COVID-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Moreover, the effects of abidol, oseltamivir or methylprednisolone in SARS-
CoV-2 infection have not been fully evaluated.

This study has several limitations. First, the virus loads were not detected. We can’t determine if the MODS or severity of illness were correlated with the sustained viral load. Secondly, due to the retrospective study, data about the values of creatine kinase, creatine kinase-MB and lactate dehydrogenase from day 11 to day 17 were missing. The enzyme activity couldn’t be analyzed in week 3 after illness onset. Further study should be conducted to clarify the dynamic change of the three lab index. Third, only 107 patients with confirmed SARS-CoV-2 infection were enrolled in this study. Future study should be needed to enroll larger sample sizes to evaluate the clinical course and analyze the risk factor for death in COVID-19.

Conclusions
Our experience in Wuhan revealed a period of 7–13 days after the onset of illness as the critical stage in COVID-19 course. Age and male gender were independent risk factors for death of COVID-19.

List Of Abbreviations
COVID-19, Coronavirus Disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; MERS, Middle East respiratory syndrome; AKI, acute kidney injury; ARDS, acute respiratory dyspnea syndrome; IQR, interquartile range; NAAT, nucleic acid amplification test; PT, prothrombin time; APACHE II score, Acute Physiology and Chronic Health Evaluation II score; ECMO, extracorporeal membrane oxygenation; MODS, multiple organ dysfunction syndrome; ACE2, angiotensin converting enzyme 2

Declarations

Ethics approval and consent to participate
This case series was approved by the institutional ethics board of Zhongnan Hospital of Wuhan University and Xishui People’s Hospital (No. 2020020).

Consent for publication
No individual participant data is reported that would require consent to publish from the participant (or legal parent or guardian for children).
**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by the National Natural Science Foundation (grant 81701941 to Dr D Wang; grants 81772046 and 81971816 to Dr Peng) and the Special Project for Significant New Drug Research and Development in the Major National Science and Technology Projects of China (2020ZX09201007 to Dr Peng).

**Authors’ contributions**

Both Drs Wang and Peng designed this project. Drs. Yin, Liu, Zhang, Zhou and B.Hu collected the data. Dr C Hu and M Jian were responsible for the statistical analysis. Dr Wang wrote the draft and Drs Xu, Li, Prowly, and Peng revised this draft. Dr Peng finalized this manuscript and all the authors approved the final version of this manuscript.

**Acknowledgments:** We would like to thank the staff of the department of Critical Care Medicine of Xi-Shui Hospital, Huanggang, Hubei Province, who contributed to this study by collecting the required data in the hospital data system.

**References**

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; doi:10.1056/NEJMoa2002032.

2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. Published Online First 24 January 2020.
3. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 2012;367(19):1814–1820. doi:10.1056/NEJMoa1211721.

4. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Published Online First 30 January 2020. doi:10.1016/S0140-6736(20)30251-8.

5. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Published Online First 3 February 2020. doi:10.1038/s41586-020-2012-7.

6. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.* Published Online First 29 January 2020. doi:10.1056/NEJMoa2001316.

7. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Published Online First 24 January 2020. doi:10.1016/S0140-6736(20)30154-9.

8. Phan LT, Nguyen TV, Luong QC, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. *N Engl J Med.* Published Online First 28 January 2020. doi:10.1056/NEJMc2001272.

9. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med.* Published Online First 30 January 2020. doi:10.1056/NEJMc2001468.

10. Yang Y, Lu QB, Liu MJ, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. Preprint. Published Online First 3 February 2020. doi:
11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Published Online First 24 January 2020. doi:10.1016/S0140-6736(20)30183-5.

12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Published Online First 30 January 2020. doi:10.1016/S0140-6736(20)30211-7.

13. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Published Online First 7 February 2020. doi:10.1001/jama.2020.1585.

14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; doi:10.1016/S0140-6736(20)30566-3.

15. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020; https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected

16. Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307(23):2526-2533. doi:10.1001/jama.2012. 5669.

17. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury Kidney Int Suppl 2012; 2:1.

18. Zhao Y, Zhao ZX, Wang YJ, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Preprint. bioRxiv. 2020; https://doi.org/10.1101/2020.01.26.919985
19. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; doi:10.1038/s41564-020-0688-y.

20. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. Published Online First 31 January 2020. doi:10.1056/NEJMo2001191.

21. Zhang H, Kang ZJ, Gong HY, et al. The digestive system is a potential route of 2019 nCoV infection: a bioinformatics analysis based on single-cell transcriptomes. Preprint. 2020; https://doi.org/10.1101/2020.01.30.927806

22. Clinical Trials. https://clinicaltrials.gov/ct2/results?cond=2019-nCoV (accessed Feb 22, 2020).

23. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. Published Online First 4 February 2020. doi:10.1038/s41422-020-0282-0.

24. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; doi:10.1056/NEJMo2001282.

Tables
Table 1: Baseline characteristics of COVID-19 Patients.
| Characteristics                  | Total (n=107) | Survivors (n=88) | Non-survivors (n=19) | P Value |
|---------------------------------|--------------|------------------|----------------------|---------|
| **Age, years**                  |              |                  |                      |         |
| 45                              | 51(36.0-65.0) | 44(35.0-58.8)    | 73(64.0-81.0)        | <0.001* |
| 45-59                           | 46(43.0)     | 44(50.0)         | 2(10.5)              | 0.002   |
| 60-75                           | 25(23.4)     | 24(27.3)         | 1(5.3)               | 0.041   |
| 75                              | 13(12.1)     | 4(4.5)           | 9(47.4)              | <0.001* |
| **Sex**                         |              |                  |                      |         |
| Male                            | 57(53.3)     | 41(46.6)         | 16(84.2)             | 0.003*  |
| Female                          | 50(46.7)     | 47(53.4)         | 3(15.8)              |         |
| **Comorbidity**                 |              |                  |                      |         |
| Any comorbidity*                | 41(38.3)     | 28(31.8)         | 13(68.4%)            | 0.003   |
| Hypertension                    | 26(24.3)     | 16(18.2)         | 10(52.6)             | 0.001*  |
| Cardiovascular disease          | 13(12.1)     | 6(6.8)           | 7(36.8)              | 0.002*  |
| Diabetes                        | 11(10.3)     | 6(6.8)           | 5(26.3)              | 0.024*  |
| Chronic liver disease           | 6(5.6)       | 5(5.7)           | 1(5.3)               | 1.000   |
| Cerebrovascular disease         | 6(5.6)       | 3(3.4)           | 3(15.8)              | 0.068   |
| COPD                            | 3(2.8)       | 2(2.3)           | 1(5.3)               | 0.447   |
| Chronic kidney disease          | 3(2.8)       | 2(2.3)           | 1(5.3)               | 0.447   |
| **Symptoms and signs**          |              |                  |                      |         |
| Fever                           | 104(97.2)    | 85(96.6)         | 19(100.0)            | 1.000   |
| Dry cough                       | 67(62.6)     | 56(63.6)         | 11(57.9)             | 0.639   |
| Fatigue                         | 69(64.5)     | 55(62.5)         | 14(73.7)             | 0.356   |
| Dyspnea                         | 35(32.7)     | 20(22.7)         | 15(78.9)             | <0.001* |
| Anorexia                        | 33(30.8)     | 25(28.4)         | 8(42.1)              | 0.241   |
| Myalgia                         | 33(30.8)     | 28(31.8)         | 5(26.3)              | 0.638   |
| Pharyngalgia                    | 12(11.2)     | 11(12.5)         | 1(5.3)               | 0.689   |
| Headache                        | 7(6.5)       | 7(8.0)           | 0(0)                 | 0.348   |
| Dizziness                       | 7(6.5)       | 7(8.0)           | 0(0)                 | 0.348   |
| Diarrhea                        | 7(6.5)       | 3(3.4)           | 4(21.1)              | 0.018*  |
| Nausea                          | 6(5.6)       | 6(6.8)           | 0(0)                 | 0.588   |
| Vomiting                        | 3(2.8)       | 2(2.3)           | 1(5.3)               | 0.447   |
| Abdominal pain                  | 2(1.9)       | 1(1.1)           | 1(5.3)               | 0.325   |
| Heart rate (bpm)                | 86(75-96)    | 85(75-96)        | 90(78-100)           | 0.240   |
| Respiratory rate                | 20(19-21)    | 20(19-21)        | 22(20-24)            | 0.003*  |
| Mean arterial pressure (mmHg)   | 89(83-98)    | 88(83-96)        | 95(89-101)           | 0.019*  |
| Onset of symptom to admission (d)| 7.0(3.5-9.0) | 7.0(3.0-9.8)    | 6.0(4.0-7.0)         | 0.405   |
| Onset of symptom to dyspnea (d) | 5.5(2.0-9.3) | 7.0(3.3-10.8)   | 4.0(1.8-7.5)         | 0.103   |
| Onset of symptom to ARDS (d)    | 7.5(4.3-11.0)| 10.0(6.0-13.0)  | 7.0(3.5-9.0)         | 0.081   |
| Length of hospital stay (d)     | 11.0(7.0-15.0)| 10.5(7.0-14.0) | 14.0(6.0-17.0)       | 0.561   |

Data expressed as median (IQR) or N (%)

Abbreviations: COPD, chronic obstructive pulmonary disease; ARDS, acute respiratory distress syndrome; bpm, beats per minute.

Data are median (IQR), n (%). p values indicate differences between survivors and non-survivors. P <
0.05 was considered as significant. Vital signs including heart rate, respiratory rate and mean arterial pressure were collected at admission. *one patient had the comorbidity of lung cancer and died of ARDS.

Table 2: Laboratory Values and Radiographic Findings at admission of COVID-19 Patients.

|                         | Normal range | Total (n=107) | Survivors (n=88) | Non-survivors (n=19) | P Value |
|-------------------------|--------------|---------------|------------------|----------------------|---------|
| White blood cell count, × 10⁹/L | 3.5-9.5      | 4.6(3.7-6.1)  | 4.4(3.4-5.8)     | 6.7(4.6-10.3)        | 0.004*  |
| Neutrophil count, × 10⁹/L    | 1.8-6.3      | 3.1(2.1-4.7)  | 2.8(2.0-3.9)     | 5.4(3.2-8.5)         | <0.001* |
| Lymphocyte count, × 10⁹/L    | 1.1-3.2      | 0.9(0.7-1.2)  | 0.9(0.7-1.3)     | 0.8(0.5-1.1)         | 0.121   |
| Platelet count, × 10⁹/L      | 125-350      | 175(129-200)  | 178(139-207)     | 122(83-178)          | 0.006*  |
| Prothrombin time, s         | 9.4-12.5     | 12.8(11.9-13.5)| 12.9(12.0-13.5)  | 12.6(11.9-13.5)      | 0.813   |
| Activated partial thromboplastin time, s | 25.1-36.5 | 31.7(29.4-33.9) | 31.7(29.5-33.5) | 32.7(27.5-37.0) | 0.850   |
| D-dimer, mg/L               | 0-500        | 203(121-358)  | 191(108-327)     | 439(202-1991)        | 0.003*  |
| Creatine kinase, U/L        | <171         | 90(54-138)    | 86(53-121)       | 142(87-325)          | 0.022*  |
| Creatine kinase-MB, U/L     | <25          | 14(10-18)     | 13(9-16)         | 18(13-44)            | 0.008*  |
| Lactate dehydrogenase, U/L  | 125-243      | 236(176-369)  | 227(171-329)     | 456(254-588)         | 0.010*  |
| Alanine aminotransferase, U/L| 9-50         | 23(16-39)     | 22(15-34)        | 47(22-66)            | 0.002*  |
| Aspartate aminotransferase, U/L| 15-40       | 31(24-47)     | 29(23-41)        | 67(38-90)            | <0.001* |
| Total bilirubin, mmol/L      | 5-21         | 9.8(8.4-14.1) | 9.5(8.4-12.9)    | 11.3(9.4-20.7)       | 0.069   |
| Blood urea nitrogen, mmol/l  | 2.8-7.6      | 4.2(3.2-5.6)  | 3.9(3.0-4.7)     | 6.1(4.9-10.5)        | <0.001* |
| Creatinine, μmol/L           | 64-104       | 71(60-86)     | 68(58-83)        | 87(71-130)           | <0.001* |
| Hypersensitive troponin I, > 26.2pg/mL, No. (%) | <26.2          | 6(5.6)        | 1(1.1)           | 5(26.3)              | 0.001*  |
| Multilobar involvement on initial radiographs, No. (%) | NA          | 90(84.1)      | 73(83.0)         | 17(89.5)             | 0.731   |
| Bilateral involvement on radiographs during hospitalization, No. (%) | NA          | 105(98.1)     | 86(97.7)         | 19(100.0)            | 1.000   |

Abbreviations: MB, muscle and brain type; NA, not available.

Data are median (IQR), or n (%). P values indicate differences between survivors and non-survivors. P < 0.05 was considered as significant. Laboratory values and radiographic findings were collected at admission except that the bilateral involvement on radiographs was collected during hospitalization.
### Table 3: Complications and Treatment Measure of COVID-19 Patients.

| Complications                  | Total (n=107) | Survivors (n=88) | Non-survivors (n=19) |
|--------------------------------|---------------|------------------|---------------------|
| Shock                          | 22(20.6)      | 3(3.4)           | 19(100.0)           |
| Acute cardiac injury           | 12(11.2)      | 4(4.5)           | 8(42.1)             |
| ARDS                           | 28(26.2)      | 11(12.5)         | 17(89.5)            |
| Acute kidney injury            | 14(13.1)      | 0(0.0)           | 14(73.7)            |
| Evidence of co-infection       |               |                  |                     |
| Bacterial a                    | 5(4.7)        | 1(1.1)           | 4(21.1)             |
| Viral b                        | 12(11.2)      | 10(11.4)         | 2(10.5)             |
| Treatment                      |               |                  |                     |
| Antiviral therapy              | 105(98.1 %)   | 87(98.9)         | 18(94.7)            |
| Oseltamivir                    | 95(88.8 %)    | 77(87.5)         | 18(94.7)            |
| Arbidol                        | 33(30.8 %)    | 33(37.5)         | 0(0.0)              |
| Antibiotic therapy             | 85(79.4 %)    | 67(76.1)         | 18(94.7)            |
| Glucocorticoid therapy         | 62(57.9 %)    | 44(50.0)         | 18(94.7)            |
| CRRT                           | 4(3.7)        | 0(0.0)           | 4(21.1)             |
| Oxygen therapy                 |               |                  |                     |
| Oxygen inhalation              | 80(74.8 %)    | 78(88.6)         | 2(10.5)             |
| Non-invasive ventilation       | 7(6.5)        | 7(8.0)           | 0(0.0)              |
| IMV alone                      | 17(15.9 %)    | 1(1.1)           | 16(84.2)            |
| IMV plus ECMO                  | 3(2.8)        | 2(2.3)           | 1(5.3)              |

Abbreviations: ARDS, acute respiratory distress syndrome; CRRT, Continuous renal replacement therapy; IMV, invasive mechanical ventilation; ECMO, extracorporeal membrane oxygenation.

Data are n (%). P values indicate differences between survivors and non-survivors. P < 0.05 was considered as significant.

### Table 4: Univariate Analysis of Variable Associated With Death For COVID-19 Patients.

| Variable                                  | Univariable OR (95% CI) | P Value |
|-------------------------------------------|-------------------------|---------|
| Age                                       | 1.102(1.054-1.152)      | <0.001* |
| Male                                      | 6.114(1.662-22.485)     | 0.006*  |
| Hypertension                              | 5.000(1.748-14.301)     | 0.003*  |
| Diabetes                                  | 4.881(1.310-18.184)     | 0.018*  |
| Cardiovascular disease                    | 7.972(2.290-27.753)     | 0.001*  |
| White blood cell count                    | 1.239(1.055-1.455)      | 0.009*  |
| Neutrophil count                          | 1.257(1.073-1.472)      | 0.005*  |
| Lymphocyte count                          | 0.234(0.051-1.075)      | 0.062   |
| Platelet count                            | 0.987(0.977-0.997)      | 0.009*  |
| Prothrombin time                          | 1.084(0.737-1.595)      | 0.683   |
| Activated partial thromboplastin time     | 0.998(0.979-1.017)      | 0.829   |
| Creatine kinase                           | 1.001(0.999-1.002)      | 0.277   |
| Creatine kinase-MB                        | 1.043(1.008-1.079)      | 0.015*  |
| Lactate dehydrogenase                     | 1.006(1.002-1.010)      | 0.004*  |
| Alanine aminotransferase                  | 1.020(1.002-1.038)      | 0.031*  |
| Aspartate aminotransferase                | 1.034(1.015-1.054)      | <0.001* |
| Total bilirubin                           | 1.070(0.995-1.149)      | 0.066   |
| Blood urea nitrogen                       | 1.001(0.985-1.016)      | 0.943   |
| Creatinine                                | 1.037(1.015-1.058)      | 0.001*  |
| Tamiflu                                   | 0.389(0.047-3.209)      | 0.380   |
Abbreviations: MB, muscle and brain type.

P < 0.05 was considered as significant and labeled with an asterisk (*) at the top corner of the P value.

Table 5: Univariate and Multivariate Analysis of Risk Factors Associated With Death for COVID-19 patients.

| Variable                  | Univariable OR (95% CI) | P Value | Multivariable OR (95% CI) | P Value |
|---------------------------|-------------------------|---------|---------------------------|---------|
| Age (years)               | 1.102(1.054-1.152)      | <0.001* | 1.111(1.042-1.184)        | 0.001*  |
| Male                      | 6.114(1.662-22.485)     | 0.006*  | 7.224(1.298-40.190)       | 0.024*  |
| Hypertension              | 5.000(1.748-14.301)     | 0.003*  | 1.099(0.264-4.580)        | 0.897   |
| Cardiovascular disease    | 7.972(2.290-27.753)     | 0.001*  | 1.188(0.182-7.765)        | 0.857   |
| Creatinine concentration  | 1.037(1.015-1.058)      | 0.001*  | 1.012(0.987-1.037)        | 0.342   |

P < 0.05 was considered as significant and labeled with an asterisk (*) at the top corner of the P value.

Supplementary Figure Legend

**Supplementary Figure 1. Dynamic Body Temperature and Laboratory Findings in 107 COVID-19 Patients.** Timeline charts illustrate the temperature and laboratory parameters in 107 patients with COVID-19 (88 survivors and 19 non-survivors) every other day based on the days after the onset of illness. The dashed lines in red show the upper normal limit of each parameter, and the dashed line in blue shows the lower normal limit of lymphocyte count. * P <0 .05 for survivors vs non-survivors.

Figures
Temporal clinical profiles in 107 patients with COVID-19. % of positive NAAT: percentage of patients who showed positive NAAT for the first time.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
Supplementary Figure 1.docx